The Renin-Angiotensin System in Liver Disease

被引:7
作者
McGrath, Mary S. [1 ]
Wentworth, Brian J. [2 ]
机构
[1] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22903 USA
[2] Univ Virginia, Sch Med, Div Gastroenterol & Hepatol, Charlottesville, VA 22903 USA
关键词
angiotensin II; angiotensin; 1-7; classical pathway; alternative pathway; cirrhosis; II RECEPTOR ANTAGONIST; ACUTE KIDNEY INJURY; CONVERTING ENZYME-INHIBITORS; LOWERING PORTAL PRESSURE; CIRRHOTIC-PATIENTS; NITRIC-OXIDE; HEPATITIS-C; ENDOTHELIAL DYSFUNCTION; HYPERTENSIVE PATIENTS; HEPATORENAL-SYNDROME;
D O I
10.3390/ijms25115807
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The renin-angiotensin system (RAS) is a complex homeostatic entity with multiorgan systemic and local effects. Traditionally, RAS works in conjunction with the kidney to control effective arterial circulation, systemic vascular resistance, and electrolyte balance. However, chronic hepatic injury and resulting splanchnic dilation may disrupt this delicate balance. The role of RAS in liver disease, however, is even more extensive, modulating hepatic fibrosis and portal hypertension. Recognition of an alternative RAS pathway in the past few decades has changed our understanding of RAS in liver disease, and the concept of opposing vs. "rebalanced" forces is an ongoing focus of research. Whether RAS inhibition is beneficial in patients with chronic liver disease appears to be context-dependent, but further study is needed to optimize clinical management and reduce organ-specific morbidity and mortality. This review presents the current understanding of RAS in liver disease, acknowledges areas of uncertainty, and describes potential areas of future investigation.
引用
收藏
页数:23
相关论文
共 164 条
[1]  
Abdelhamid A M, 2022, Eur Rev Med Pharmacol Sci, V26, P5285, DOI 10.26355/eurrev_202207_29320
[2]   The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort [J].
Abu Dayyeh, Barham K. ;
Yang, May ;
Dienstag, Jules L. ;
Chung, Raymond T. .
DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (02) :564-568
[3]   Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease [J].
Agasti, Ananta Kumar ;
Mahajan, Ajay U. ;
Phadke, Aniruddha Y. ;
Nathani, Pratap J. ;
Sawant, Prabha .
JOURNAL OF DIGESTIVE DISEASES, 2013, 14 (05) :266-271
[4]   The renin-angiotensin system and malignancy [J].
Ager, Eleanor I. ;
Neo, Jaclyn ;
Christophi, Christopher .
CARCINOGENESIS, 2008, 29 (09) :1675-1684
[5]   Role of renin-angiotensin system in liver diseases: an outline on the potential therapeutic points of intervention [J].
Ahmadian, Elham ;
Pennefather, Peter S. ;
Eftekhari, Aziz ;
Heidari, Reza ;
Eghbal, Mohammad Ali .
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (11) :1279-1288
[6]  
Alam I, 2000, AM J GASTROENTEROL, V95, P199
[7]   Oxidative Stress in Liver Pathophysiology and Disease [J].
Allameh, Abdolamir ;
Niayesh-Mehr, Reyhaneh ;
Aliarab, Azadeh ;
Sebastiani, Giada ;
Pantopoulos, Kostas .
ANTIOXIDANTS, 2023, 12 (09)
[8]   Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis [J].
Angeli, Paolo ;
Merkel, Carlo .
JOURNAL OF HEPATOLOGY, 2008, 48 :S93-S103
[9]   Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity [J].
Baik, SK ;
Park, DH ;
Kim, MY ;
Choi, YJ ;
Kim, HS ;
Lee, DK ;
Kwon, SO ;
Kim, YJ ;
Park, JW ;
Chang, SJ .
JOURNAL OF GASTROENTEROLOGY, 2003, 38 (12) :1150-1154
[10]   Sodium Retention in Heart Failure and Cirrhosis Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? [J].
Bansal, Shweta ;
Lindenfeld, JoAnn ;
Schrier, Robert W. .
CIRCULATION-HEART FAILURE, 2009, 2 (04) :370-376